Reforms to telehealth and insulin pricing are stalled in Congress despite notable progress on health care policies like enhanced marketplace subsidies in recent days. D.C. insiders tell AIS Health, a division of MMIT, that comprehensive fixes to either issue are unlikely to make their way into the landmark Inflation Reduction Act of 2022 (IRA), which seems poised to pass the Senate.
Telehealth reforms have passed the House of Representatives, but insiders tell AIS Health that they are unlikely to pass the Senate. They are also not expected to be included as part of a final version of the IRA, which should emerge in the coming days. Some insulin reforms may be included in the IRA, but D.C. experts expect that reforms affecting the commercial market are unlikely to pass as part of the bill. Instead, the insulin price changes are likely to be restricted to Medicare.